Trabert B, et al. - In order to gauge the relationship of analgesic use with ovarian cancer, experts evaluated the data from 13 studies in the Ovarian Cancer Cohort Consortium (OC3). A slightly lower risk of developing ovarian cancer (about 10% lower than infrequent/nonuse) was seen in the women who use aspirin daily, which is similar to the risk reduction observed in case-control analyses.

Methods

• In this current study, authors included 758,829 women who self-reported analgesic use at study enrollment; 3,514 of whom developed ovarian cancer.
• Using Cox regression, researchers evaluated the relationship between frequent medication use and risk of ovarian cancer; they also assessed the dose and duration.
• All statistical tests that were conducted were two-sided.

Results

• Findings suggested that a 10% reduction in ovarian cancer risk was seen in women who used aspirin almost daily (≥ 6 days/week) vs infrequent/nonuse (rate ratio [RR]=0.90, 95% confidence interval [CI]=0.82 to 1.00, P=.05).
• As per data, frequent use (≥ 4 days/week) of aspirin (RR=0.95, 95% CI=0.88 to 1.03), nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs; R =1.00, 95% CI=0.90 to 1.11), or acetaminophen (RR=1.05, 95% CI=0.88 to 1.24) was not associated with risk.
• Results demonstrated an association of daily acetaminophen use (RR=1.28, 95% CI=1.00 to 1.65, P=.05) with elevated ovarian cancer risk.
• Researchers noted that for frequent, long-term (10+ years) use of aspirin (RR=1.15, 95% CI=0.98 to 1.34) or nonaspirin NSAIDs (RR=1.19, 95% CI=0.84 to 1.68), risk estimates were modestly elevated, although not statistically significantly so.